Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction that occurred on Wednesday, May 7th. The shares were sold at an average price of $18.39, for a total value of $122,606.13. Following the transaction, the chief operating officer now owns 309,976 shares of the company’s stock, valued at approximately $5,700,458.64. This represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Anish Patel also recently made the following trade(s):

• On Monday, April 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.04, for a total transaction of $120,272.68.
• On Friday, March 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.44, for a total transaction of $142,940.48.

Enliven Therapeutics Trading Down 0.6 %

Shares of ELVN opened at $18.51 on Friday. The firm has a market cap of $908.21 million, a P/E ratio of -9.74 and a beta of 1.07. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03. The stock’s 50 day moving average is $19.06 and its two-hundred day moving average is $22.04.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. Equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Institutional Trading of Enliven Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ELVN. Invesco Ltd. lifted its stake in Enliven Therapeutics by 3.5% in the 4th quarter. Invesco Ltd. now owns 15,072 shares of the company’s stock valued at $339,000 after buying an additional 508 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Enliven Therapeutics by 3.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company’s stock valued at $451,000 after acquiring an additional 718 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after acquiring an additional 1,114 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Enliven Therapeutics by 14.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock worth $233,000 after acquiring an additional 1,275 shares during the last quarter. Finally, MetLife Investment Management LLC increased its position in shares of Enliven Therapeutics by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 21,746 shares of the company’s stock worth $489,000 after purchasing an additional 1,285 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright lifted their price objective on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a report on Friday, March 21st.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.